NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
Clinical Trials
3 trialsNCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
NCT03794440 2021-01-22
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2/3 Unknown